Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting. Xtampza ER is designed to provide adequate pain control while maintaining its extended-release drug release profile after being subjected to common methods of abuse and accidental misuse. ONSOLIS is a Transmucosal Immediate-Release Fentanyl (TIRF) film indicated for the management of breakthrough pain in cancer patients (BTPc), 18 years of age and older, who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Pharmaceuticals
- Sub-Industry: N/A
- Symbol: NASDAQ:COLL
- CUSIP: N/A
- Web: www.collegiumpharma.com
Capitalization:- Market Cap: $297.44 million
- Outstanding Shares: 29,566,000
Average Prices:- 50 Day Moving Avg: $10.41
- 200 Day Moving Avg: $10.41
- 52 Week Range: $9.68 - $20.55
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -5.37
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $7.44 million
- Price / Sales: 40.97
- Book Value: $3.23 per share
- Price / Book: 3.19
Profitability:- EBIDTA: ($97,950,000.00)
- Net Margins: -1,319.39%
- Return on Equity: -93.73%
- Return on Assets: -74.81%
Debt:- Current Ratio: 4.22%
- Quick Ratio: 4.17%
Misc:- Average Volume: 269,257 shs.
- Beta: -0.12
- Short Ratio: 20.34
Frequently Asked Questions for Collegium Pharmaceutical (NASDAQ:COLL)
What is Collegium Pharmaceutical's stock symbol?
Collegium Pharmaceutical trades on the NASDAQ under the ticker symbol "COLL."
How were Collegium Pharmaceutical's earnings last quarter?
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) released its earnings results on Wednesday, August, 9th. The company reported ($0.72) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.81) by $0.09. The firm earned $3.56 million during the quarter, compared to the consensus estimate of $4.07 million. Collegium Pharmaceutical had a negative net margin of 1,319.39% and a negative return on equity of 93.73%. View Collegium Pharmaceutical's Earnings History.
When will Collegium Pharmaceutical make its next earnings announcement?
Where is Collegium Pharmaceutical's stock going? Where will Collegium Pharmaceutical's stock price be in 2017?
5 brokerages have issued 12 month target prices for Collegium Pharmaceutical's shares. Their forecasts range from $14.00 to $25.00. On average, they expect Collegium Pharmaceutical's share price to reach $20.00 in the next twelve months. View Analyst Ratings for Collegium Pharmaceutical.
Who are some of Collegium Pharmaceutical's key competitors?
Some companies that are related to Collegium Pharmaceutical include SciClone Pharmaceuticals (SCLN), Corium International (CORI), Teligent (TLGT), Tetraphase Pharmaceuticals (TTPH), Aceto Corporation (ACET), Aquinox Pharmaceuticals (AQXP), Neos Therapeutics (NEOS), Allergy Therapeutics plc (AGY), Adamis Pharmaceuticals Corporation (ADMP), BioDelivery Sciences International (BDSI), Marinus Pharmaceuticals (MRNS), Aralez Pharmaceuticals (ARLZ), BioLife Solutions (BLFS), Diurnal Group PLC (DNL), Concordia International Corp. (CXRX), SCYNEXIS (SCYX), Evoke Pharma (EVOK) and Juniper Pharmaceuticals (JNP).
Who are Collegium Pharmaceutical's key executives?
Collegium Pharmaceutical's management team includes the folowing people:
- Michael Thomas Heffernan, Chairman of the Board, President, Chief Executive Officer
- Paul Brannelly CPA, Chief Financial Officer, Executive Vice President
- Joseph J. Ciaffoni, Chief Operating Officer, Executive Vice President
- Douglas R. Carlson, Vice President - Corporate Development
- Alison B Fleming, Vice President of Product Development
- Ernest A. Kopecky Ph.D., Vice President - Clinical Development and Head of Neuroscience
- Kevin OKeeffe, Vice President - Market Access and Trade
- Steven Passik Ph.D., Vice President - Scientific Affairs, Education and Policy
- Said Saim Ph.D., Vice President of Pharmaceutical Development
- John Weet Ph.D., Vice President - Regulatory Affairs and Quality Assurance
When did Collegium Pharmaceutical IPO?
(COLL) raised $75 million in an initial public offering on Thursday, May 7th 2015. The company issued 5,800,000 shares at $12.00-$14.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and Wells Fargo Securities and Needham & Company were co-managers.
Who owns Collegium Pharmaceutical stock?
Collegium Pharmaceutical's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Franklin Resources Inc. (7.48%), Frazier Management LLC (6.38%), Sectoral Asset Management Inc (6.12%), TPG Group Holdings SBS Advisors Inc. (4.70%), Macquarie Group Ltd. (3.78%) and Vanguard Group Inc. (2.68%). Company insiders that own Collegium Pharmaceutical stock include John A Fallon and Paul Brannelly. View Institutional Ownership Trends for Collegium Pharmaceutical.
Who sold Collegium Pharmaceutical stock? Who is selling Collegium Pharmaceutical stock?
Who bought Collegium Pharmaceutical stock? Who is buying Collegium Pharmaceutical stock?
Collegium Pharmaceutical's stock was acquired by a variety of institutional investors in the last quarter, including Sectoral Asset Management Inc, Macquarie Group Ltd., Granite Investment Partners LLC, Northern Trust Corp, State Street Corp, Bank of New York Mellon Corp, Bradley Foster & Sargent Inc. CT and Teachers Advisors LLC. Company insiders that have bought Collegium Pharmaceutical stock in the last two years include John A Fallon and Paul Brannelly. View Insider Buying and Selling for Collegium Pharmaceutical.
How do I buy Collegium Pharmaceutical stock?
Shares of Collegium Pharmaceutical can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Collegium Pharmaceutical's stock price today?
One share of Collegium Pharmaceutical stock can currently be purchased for approximately $10.31.
MarketBeat Community Rating for Collegium Pharmaceutical (NASDAQ COLL)MarketBeat's community ratings are surveys of what our community members think about Collegium Pharmaceutical and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Earnings History for Collegium Pharmaceutical (NASDAQ:COLL)Earnings History by Quarter for Collegium Pharmaceutical (NASDAQ COLL)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/8/2017 | | ($0.75) | | | | | N/A |  |
| 8/9/2017 | Q2 2017 | ($0.81) | ($0.72) | $4.07 million | $3.56 million | View | Listen | |
| 5/10/2017 | Q1 2017 | ($0.98) | ($0.79) | $3.55 million | $2.17 million | View | N/A | |
| 3/9/2017 | Q4 2016 | ($1.07) | ($1.02) | $1.79 million | $1.30 million | View | Listen | |
| 11/10/2016 | Q3 2016 | ($1.09) | ($1.13) | $1.00 million | $0.41 million | View | Listen | |
| 8/10/2016 | Q2 | ($0.76) | ($1.05) | $0.16 million | | View | Listen | |
| 5/10/2016 | Q1 | ($0.60) | ($0.68) | | | View | Listen | |
| 3/15/2016 | Q415 | ($0.45) | ($0.46) | | | View | Listen | |
| 11/12/2015 | Q315 | ($0.30) | ($0.46) | | | View | Listen | |
| 8/12/2015 | Q215 | ($0.26) | ($0.45) | | | View | Listen | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Collegium Pharmaceutical (NASDAQ:COLL)2017 EPS Consensus Estimate: ($3.22)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($0.89) | ($0.89) | ($0.89) |
| Q2 2017 | 2 | ($0.81) | ($0.76) | ($0.79) |
| Q3 2017 | 2 | ($0.81) | ($0.67) | ($0.74) |
| Q4 2017 | 2 | ($1.00) | ($0.61) | ($0.81) |
(Data provided by Zacks Investment Research)
Dividend History for Collegium Pharmaceutical (NASDAQ:COLL)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Collegium Pharmaceutical (NASDAQ:COLL)Insider Ownership Percentage: 25.76%
Institutional Ownership Percentage: 83.04%
Insider Trades by Quarter for Collegium Pharmaceutical (NASDAQ:COLL)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 5/12/2017 | Paul Brannelly | Insider | Buy | 10,000 | $9.18 | $91,800.00 | |
| 8/12/2016 | John A Fallon | Director | Buy | 2,375 | $10.59 | $25,151.25 | |
| 5/12/2015 | John Gordon Freund | Director | Buy | 150,000 | $12.00 | $1,800,000.00 | |
| 5/12/2015 | Longitude Capital Partners, Ll | Major Shareholder | Buy | 200,000 | $12.00 | $2,400,000.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Collegium Pharmaceutical (NASDAQ:COLL)
Latest Headlines for Collegium Pharmaceutical (NASDAQ:COLL)
| Source: |
|
| Date | Headline |
|---|
 | Collegium Pharmaceutical, Inc. (COLL) Receives "Buy" Rating from Jefferies Group LLC
www.americanbankingnews.com - September 22 at 12:38 AM |
| Collegium Pharmaceutical, Inc. (COLL) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - September 20 at 9:24 AM |
 | Benzinga's Top Upgrades, Downgrades For September 11, 2017 - Benzinga
www.benzinga.com - September 11 at 6:04 PM |
| Collegium Pharmaceutical's (COLL) Buy Rating Reiterated at Piper Jaffray Companies
www.americanbankingnews.com - September 9 at 3:06 PM |
 | Collegium to Present at Upcoming Investor Conferences - GlobeNewswire (press release)
globenewswire.com - September 6 at 5:23 PM |
| Collegium Announces Scientific Presentations at PAINWeek 2017 Meeting - GlobeNewswire (press release)
globenewswire.com - September 5 at 11:57 PM |
| Collegium Pharmaceutical, Inc. (COLL) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - August 26 at 9:26 AM |
 | BioDelivery (BDSI) CEO Mark Sirgo to Retire by 2017 End - Nasdaq
www.nasdaq.com - August 24 at 10:39 PM |
| $5.03 Million in Sales Expected for Collegium Pharmaceutical, Inc. (COLL) This Quarter
www.americanbankingnews.com - August 23 at 11:32 AM |
 | Collegium Pharmaceutical, Inc. – Value Analysis (NASDAQ:COLL) : August 17, 2017
finance.yahoo.com - August 16 at 10:51 PM |
| Zacks Investment Research Upgrades Collegium Pharmaceutical, Inc. (NASDAQ:COLL) to "Hold"
www.americanbankingnews.com - August 14 at 10:34 PM |
| FY2017 Earnings Estimate for Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Issued By Gabelli
www.americanbankingnews.com - August 14 at 5:52 AM |
| Jefferies Group Weighs in on Collegium Pharmaceutical, Inc.'s Q3 2017 Earnings (COLL)
www.americanbankingnews.com - August 14 at 3:18 AM |
| William Blair Comments on Collegium Pharmaceutical, Inc.'s Q3 2017 Earnings (COLL)
www.americanbankingnews.com - August 14 at 3:18 AM |
| FY2020 EPS Estimates for Collegium Pharmaceutical, Inc. Lifted by Gabelli (NASDAQ:COLL)
www.americanbankingnews.com - August 11 at 5:22 PM |
| Edited Transcript of COLL earnings conference call or presentation 9-Aug-17 8:30pm GMT
finance.yahoo.com - August 10 at 11:40 PM |
| Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Issues Quarterly Earnings Results, Beats Estimates By $0.09 EPS
www.americanbankingnews.com - August 10 at 11:04 PM |
| Collegium Reports Second Quarter Financial Results and Provides Corporate Update - GlobeNewswire (press release)
globenewswire.com - August 9 at 5:37 PM |
| Collegium Reports Second Quarter Financial Results and Provides Corporate Update
finance.yahoo.com - August 9 at 5:37 PM |
| Collegium Pharmaceutical posts 2Q loss
finance.yahoo.com - August 9 at 5:37 PM |
| Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Downgraded by BidaskClub
www.americanbankingnews.com - August 6 at 12:54 PM |
| Collegium Pharmaceutical, Inc. (COLL) Expected to Announce Quarterly Sales of $4.07 Million
www.americanbankingnews.com - August 5 at 9:34 AM |
| Collegium Pharmaceutical, Inc. breached its 50 day moving average in a Bearish Manner : COLL-US : August 4, 2017
finance.yahoo.com - August 4 at 5:37 PM |
| Financial Survey: Collegium Pharmaceutical (NASDAQ:COLL) and Akorn (AKRX)
www.americanbankingnews.com - August 4 at 2:26 PM |
| -$0.81 EPS Expected for Collegium Pharmaceutical, Inc. (NASDAQ:COLL) This Quarter
www.americanbankingnews.com - August 3 at 7:26 AM |
| Collegium Pharmaceutical, Inc. (COLL) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - August 1 at 8:53 AM |
| Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Scheduled to Post Earnings on Tuesday
www.americanbankingnews.com - August 1 at 7:16 AM |
| Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Given a $14.00 Price Target at Piper Jaffray Companies
www.americanbankingnews.com - July 26 at 11:59 PM |
| Collegium Pharmaceutical, Inc. Expected to Post Q2 2017 Earnings of ($0.76) Per Share (COLL)
www.americanbankingnews.com - July 20 at 8:12 AM |
| Nektar's NKTR-181 Positive in Human Abuse Potential Study - Nasdaq
www.nasdaq.com - July 19 at 6:33 PM |
| Collegium to Host Conference Call to Discuss Second Quarter 2017 Financial Results and Provide Corporate Update - Nasdaq
www.nasdaq.com - July 18 at 11:53 PM |
| Collegium to Host Conference Call to Discuss Second Quarter 2017 Financial Results and Provide Corporate Update - GlobeNewswire (press release)
globenewswire.com - July 18 at 6:52 PM |
| Collegium to Host Conference Call to Discuss Second Quarter 2017 Financial Results and Provide Corporate Update
feeds.benzinga.com - July 18 at 4:34 PM |
| Collegium Pharmaceutical Inc (COLL) Expected to Announce Quarterly Sales of $4.33 Million
www.americanbankingnews.com - July 13 at 10:48 AM |
| Edited Transcript of COLL earnings conference call or presentation 10-May-17 8:30pm GMT
finance.yahoo.com - July 11 at 11:32 PM |
| Collegium Pharmaceutical, Inc. (COLL) Downgraded by Zacks Investment Research to "Sell"
www.americanbankingnews.com - July 11 at 10:52 PM |
| -$0.80 EPS Expected for Collegium Pharmaceutical, Inc. (COLL) This Quarter
www.americanbankingnews.com - July 11 at 8:24 PM |
| Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - July 7 at 10:52 AM |
| FY2017 EPS Estimates for Collegium Pharmaceutical, Inc. Lowered by Analyst (COLL)
www.americanbankingnews.com - June 29 at 8:58 AM |
| Collegium Pharmaceutical, Inc. (COLL) Upgraded to Sell at ValuEngine
www.americanbankingnews.com - June 25 at 12:10 AM |
| Collegium Pharmaceutical, Inc. (COLL) Expected to Announce Quarterly Sales of $4.33 Million
www.americanbankingnews.com - June 17 at 8:00 AM |
| -$0.80 Earnings Per Share Expected for Collegium Pharmaceutical, Inc. (COLL) This Quarter
www.americanbankingnews.com - June 15 at 8:44 PM |
| Analyzing Pacira Pharmaceuticals (PCRX) and Collegium Pharmaceutical (COLL)
www.americanbankingnews.com - June 15 at 7:50 AM |
| Collegium Pharmaceutical, Inc. (COLL) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - June 12 at 11:00 AM |
| Collegium Pharmaceutical, Inc. (COLL) Stock Rating Reaffirmed by Janney Montgomery Scott
www.americanbankingnews.com - June 12 at 10:16 AM |
 | Why Endo's Bad News Sent Collegium Pharmaceutical Shares Soaring 10% - Motley Fool
www.fool.com - June 11 at 9:32 PM |
| Collegium Announces Scientific Presentations at the 2017 ... - GlobeNewswire (press release)
globenewswire.com - June 10 at 9:38 PM |
| Collegium's stock jumps on belief its opioid drug will get a boost from a rival's woes
finance.yahoo.com - June 10 at 3:07 AM |
| Needham & Company LLC Reaffirms Buy Rating for Collegium Pharmaceutical Inc (COLL)
www.americanbankingnews.com - June 9 at 10:48 PM |
| Collegium Announces Scientific Presentations at the 2017 International Conference on Opioids - GlobeNewswire (press release)
globenewswire.com - June 9 at 5:00 PM |
Collegium Pharmaceutical (COLL) Chart for Saturday, September, 23, 2017
